论文部分内容阅读
目的 :探讨乳腺癌骨转移诊断和随访中应用Ⅰ型胶原羧基端前肽(PICP)和β胶原降解产物(β-CTx)的价值。方法 :选取2014年3月~2015年12月在我院治疗的107例乳腺癌患者,其中49例为骨转移患者(骨转移组),58例为无骨转移患者(对照组),根据Soloway分级标准将骨转移患者分为3个亚组,A组22例(转移灶<6个),B组20例(转移灶6~20个),C组7例(转移灶>20个或超级显像)。测定患者PICP和β-CTx水平。结果 :骨转移组患者PICP和β-CTx水平分别为(110.27±30.81)ng/m L和(0.67±0.08)ng/m L,明显高于对照组,差异比较有统计学意义;不同级别骨转移组患者和对照组患者PICP和β-CTx水平比较差异有统计学意义,其中C组患者PICP和β-CTx水平最高,分别为(132.09±20.25)ng/m L和(0.83±0.11)ng/m L;对照组随访期间有5例无症状患者出现骨代谢指标异常升高,进一步诊断有3例出现骨转移。结论 :PICP和β-CTx在乳腺癌骨转移的诊断和随访中有一定的应用价值。
Objective: To investigate the value of the application of type Ⅰ collagen carboxyterminal propeptide (PICP) and β-collagen degradation product (β-CTx) in the diagnosis and follow-up of breast cancer with bone metastases. METHODS: A total of 107 breast cancer patients treated in our hospital from March 2014 to December 2015 were selected, of whom 49 were bone metastases (bone metastases) and 58 were boneless metastases (controls). According to Soloway The grading standards divided the patients with bone metastasis into three subgroups: 22 patients in group A (with metastasis less than 6), 20 patients in group B (6-20 patients with metastasis), 7 patients in group C (20 patients with metastasis or super Imaging). Patients’ PICP and β-CTx levels were determined. Results: The levels of PICP and β-CTx in bone metastasis group were (110.27 ± 30.81) ng / m L and (0.67 ± 0.08) ng / m L, respectively, which were significantly higher than those in control group The levels of PICP and β-CTx in metastasis group and control group were significantly different, the highest level of PICP and β-CTx in group C were (132.09 ± 20.25) ng / m L and (0.83 ± 0.11) ng / m L; during the follow-up period of control group, there were 5 asymptomatic patients with abnormally elevated bone metabolism index, and 3 cases were further diagnosed with bone metastasis. CONCLUSION: PICP and β-CTx have certain value in the diagnosis and follow-up of breast cancer with bone metastases.